Peer-reviewedCC BY 4.0Cancers
MTAP Loss and Pleural Mesothelioma (PM): Current Treatment Strategies and Emerging Therapeutic Approaches
- 1Medical Oncology Department, Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Hospital Universitari, 08035 Barcelona, Spain
- 2Thoracic Cancers Translational Genomics Unit, Vall d’Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain
Abstract
PM is a locally aggressive tumor associated with asbestos exposure. Despite legislative efforts to regulate asbestos use, its incidence continues to rise in some parts of the world. Chemotherapy and immunotherapy have improved survival in PM patients, but overall survival remains poor. MTAP loss is frequent in PM and may influence tumor behavior, resulting in a poorer prognosis. MTAP-deficient tumors exhibit unique metabolic vulnerabilities that have stimulated the development of targeted therapeutic strategies in recent years with promising results. The aim of this review is to analyze the prognostic and predictive value of MTAP in PM patients, as well as the outcomes of drugs with potential activity against this target.
Related
- Therapeutic Strategies After Immunotherapy Failure in Advanced Non-Small Cell Lung Cancer: Mechanisms of Resistance and Emerging Treatment Approaches
- Contemporary and Emerging Therapeutic Strategies in Hypoparathyroidism: From Conventional Treatment to Restoration of Parathyroid Function
- Sepsis-associated sarcopenia: Emerging insights into mechanisms and therapeutic approaches
- The Gut–Kidney Axis in Chronic Kidney Disease: Microbial Dysbiosis, Host–Microbial Metabolism, and Emerging Therapeutic Strategies
- Editorial: Impact of new therapeutic approaches for the treatment of post-transplant tumors on the outcome of the transplanted organ
BibTeX
@article{cedres2026mtap,
title = {{MTAP Loss and Pleural Mesothelioma (PM): Current Treatment Strategies and Emerging Therapeutic Approaches}},
author = {Susana Cedres and Laura Masfarre and Ilaria Priano and Augusto Valdivia and Pedro Rocha and Patricia Iranzo and Nuria Pardo and Alex Martinez-Marti and Aina Arbusà and Lucia Cane and Mireia Soleda and Barbara Sinigaglia and Sara Polo-Alonso and Gerard Romero-Sola and Rocio Caro-Consuegra and Ana Ortega and Enriqueta Felip},
journal = {Cancers},
year = {2026},
month = oct,
doi = {10.3390/cancers18203360},
url = {https://www.mdpi.com/2072-6694/18/20/3360},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - MTAP Loss and Pleural Mesothelioma (PM): Current Treatment Strategies and Emerging Therapeutic Approaches
AU - Susana Cedres
AU - Laura Masfarre
AU - Ilaria Priano
AU - Augusto Valdivia
AU - Pedro Rocha
AU - Patricia Iranzo
AU - Nuria Pardo
AU - Alex Martinez-Marti
AU - Aina Arbusà
AU - Lucia Cane
AU - Mireia Soleda
AU - Barbara Sinigaglia
AU - Sara Polo-Alonso
AU - Gerard Romero-Sola
AU - Rocio Caro-Consuegra
AU - Ana Ortega
AU - Enriqueta Felip
PY - 2026
DA - 2026/10/01
JO - Cancers
DO - 10.3390/cancers18203360
UR - https://www.mdpi.com/2072-6694/18/20/3360
AB - PM is a locally aggressive tumor associated with asbestos exposure. Despite legislative efforts to regulate asbestos use, its incidence continues to rise in some parts of the world. Chemotherapy and immunotherapy have improved survival in PM patients, but overall survival remains poor. MTAP loss is frequent in PM and may influence tumor behavior, resulting in a poorer prognosis. MTAP-deficient tumors exhibit unique metabolic vulnerabilities that have stimulated the development of targeted therapeutic strategies in recent years with promising results. The aim of this review is to analyze the prognostic and predictive value of MTAP in PM patients, as well as the outcomes of drugs with potential activity against this target.
SN - 2072-6694
ER -